Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydrocurcuphenol is a sesquiterpene compound and a derivative of (+)-curcuphenol, originally isolated from the Indonesian marine sponge *Myrmekioderma sp.* found in North Sulawesi. It has demonstrated significant cytotoxic activity against A549 human lung cancer cells and HeLa cervical cancer cells, with its mechanism of action linked to the induction of apoptosis as evidenced by annexin V and PI staining. Additionally, dihydrocurcuphenol exhibits potent antiviral properties against Dengue virus serotype 2 (DENV-2), showing lower EC50 values compared to its parent compound. It is currently in the early discovery and preclinical stages of research for its potential as an antineoplastic and antiviral agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydrocurcuphenol.